Creating zinc monkey wrenches in the treatment of epigenetic disorders

Current Opinion in Chemical Biology

Volumn 13, Issue 3, 2009, Pages 263-271

  Kalin, Jay Hans ^a   Butler, Kyle Vincent ^a   Kozikowski, Alan Paul ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; BONE MORPHOGENETIC PROTEIN 2; BRAIN DERIVED NEUROTROPHIC FACTOR; BUTYRIC ACID; DEPSIPEPTIDE; DNA METHYLTRANSFERASE INHIBITOR; ESTRADIOL BENZOATE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LITHIUM; MASPIN; MONOCLONAL ANTIBODY; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; PROTEIN HISTONE DEACETYLASE 8 INHIBITOR; RETINOIC ACID; ROMIDEPSIN; SIRTUIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZINC BINDING PROTEIN;

ALZHEIMER DISEASE; ANXIETY DISORDER; BIPOLAR DISORDER; COLON CANCER; DEPRESSION; EPIGENETICS; FRIEDREICH ATAXIA; GENETIC DISORDER; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; KIDNEY CARCINOMA; LEUKEMIA; MOOD DISORDER; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PANCREAS CANCER; PARKINSON DISEASE; PROSTATE CANCER; RETT SYNDROME; REVIEW; RUBINSTEIN SYNDROME; SCHIZOPHRENIA; SPINAL MUSCULAR ATROPHY;

ANIMALS; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MODELS, BIOLOGICAL; MOOD DISORDERS; NEOPLASMS; NEURODEGENERATIVE DISEASES; ZINC;

EID: 67649975232     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2009.05.007     Document Type: Review

References (64)

1. Richon V.M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., Civoli F., Breslow R., Rifkind R.A., and Marks P.A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 93 (1996) 5705-5708
2. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., and Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 95 (1998) 3003-3007
3. Marks P.A., and Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25 (2007) 84-90
4. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 (2007) 5541-5552
5. Abel T., and Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol 8 (2008) 57-64
6. Adcock I.M. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 150 (2007) 829-831
7. Witt O., Deubzer H.E., Milde T., and Oehme I. HDAC family: What are the cancer relevant targets?. Cancer Lett 277 (2009) 8-21
8. Chai G., Li L., Zhou W., Wu L., Zhao Y., Wang D., Lu S., Yu Y., Wang H., McNutt M.A., et al. HDAC inhibitors act with 5-aza-2′-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS ONE 3 (2008) e2445
9. Kuendgen A., and Lubbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol 87 (2008) 601-611
10. Kumagai T., Akagi T., Desmond J.C., Kawamata N., Gery S., Imai Y., Song J.H., Gui D., Said J., and Koeffler H.P. Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer 124 (2009) 827-833
11. Lee E.J., Lee B.B., Kim S.J., Park Y.D., Park J., and Kim D.H. Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. Int J Oncol 33 (2008) 767-776
12. Oi S., Natsume A., Ito M., Kondo Y., Shimato S., Maeda Y., Saito K., and Wakabayashi T. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells. J Neurooncol 92 (2009) 15-22
13. Beltran A.S., Sun X., Lizardi P.M., and Blancafort P. Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther 7 (2008) 1080-1090
14. Frew A.J., Lindemann R.K., Martin B.P., Clarke C.J., Sharkey J., Anthony D.A., Banks K.M., Haynes N.M., Gangatirkar P., Stanley K., et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A 105 (2008) 11317-11322
15. Nishioka C., Ikezoe T., Yang J., Koeffler H.P., and Yokoyama A. Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia 22 (2008) 1449-1452
16. Bjorkman M., Iljin K., Halonen P., Sara H., Kaivanto E., Nees M., and Kallioniemi O.P. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 123 (2008) 2774-2781
17. Khandelwal A., Gediya L., and Njar V. MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. Br J Cancer 98 (2008) 1234-1243
18. Spiller S.E., Ditzler S.H., Pullar B.J., and Olson J.M. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 87 (2008) 133-141
19. Leng Y., Liang M.H., Ren M., Marinova Z., Leeds P., and Chuang D.M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 28 (2008) 2576-2588
20. Zhu H., Huang Q., Xu H., Niu L., and Zhou J.N. Antidepressant-like effects of sodium butyrate in combination with estrogen in rat forced swimming test: involvement of 5-HT(1A) receptors. Behav Brain Res 196 (2009) 200-206
21. Pallos J., Bodai L., Lukacsovich T., Purcell J.M., Steffan J.S., Thompson L.M., and Marsh J.L. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 17 (2008) 3767-3775
22. Kozikowski A.P., Chen Y., Gaysin A.M., Savoy D.N., Billadeau D.D., and Kim K.H. Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth. ChemMedChem 3 (2008) 487-501
23. Chen Y., Lopez-Sanchez M., Savoy D.N., Billadeau D.D., Dow G.S., and Kozikowski A.P. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J Med Chem 51 (2008) 3437-3448
24. Zhou N., Moradei O., Raeppel S., Leit S., Frechette S., Gaudette F., Paquin I., Bernstein N., Bouchain G., Vaisburg A., et al. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 51 (2008) 4072-4075
25. Fournel M., Bonfils C., Hou Y., Yan P.T., Trachy-Bourget M.C., Kalita A., Liu J., Lu A.H., Zhou N.Z., Robert M.F., et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7 (2008) 759-768
26. Balakin K.V., Ivanenkov Y.A., Kiselyov A.S., and Tkachenko S.E. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem 7 (2007) 576-592
27. Elaut G., Rogiers V., and Vanhaecke T. The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des 13 (2007) 2584-2620
28. Mai A., and Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 41 (2009) 199-213
29. Kaler P., Sasazuki T., Shirasawa S., Augenlicht L., and Klampfer L. HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity. Exp Cell Res 314 (2008) 1507-1518
30. Murakami T., Sato A., Chun N.A., Hara M., Naito Y., Kobayashi Y., Kano Y., Ohtsuki M., Furukawa Y., and Kobayashi E. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol 128 (2008) 1506-1516
31. Balasubramanian S., Ramos J., Luo W., Sirisawad M., Verner E., and Buggy J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22 (2008) 1026-1034
32. Kitazoe K., Abe M., Hiasa M., Oda A., Amou H., Harada T., Nakano A., Takeuchi K., Hashimoto T., Ozaki S., et al. Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. Int J Hematol 89 (2009) 45-57
33. Cha T.L., Chuang M.J., Wu S.T., Sun G.H., Chang S.Y., Yu D.S., Huang S.M., Huan S.K., Cheng T.C., Chen T.T., et al. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 15 (2009) 840-850
34. Kozikowski A.P., Chen Y., Gaysin A., Chen B., D'Annibale M.A., Suto C.M., and Langley B.C. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J Med Chem 50 (2007) 3054-3061
35. Langley B., D'Annibale M.A., Suh K., Ayoub I., Tolhurst A., Bastan B., Yang L., Ko B., Fisher M., Cho S., et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J Neurosci 28 (2008) 163-176
36. Chen B., Petukhov P.A., Jung M., Velena A., Eliseeva E., Dritschilo A., and Kozikowski A.P. Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett 15 (2005) 1389-1392
37. Guidotti A., Dong E., Kundakovic M., Satta R., Grayson D.R., and Costa E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci 30 (2009) 55-60
38. Kazantsev A.G., and Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 7 (2008) 854-868
39. Vecsey C.G., Hawk J.D., Lattal K.M., Stein J.M., Fabian S.A., Attner M.A., Cabrera S.M., McDonough C.B., Brindle P.K., Abel T., et al. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci 27 (2007) 6128-6140
40. Fontan-Lozano A., Romero-Granados R., Troncoso J., Munera A., Delgado-Garcia J.M., and Carrion A.M. Histone deacetylase inhibitors improve learning consolidation in young and in KA-induced-neurodegeneration and SAMP-8-mutant mice. Mol Cell Neurosci 39 (2008) 193-201
41. Fischer A., Sananbenesi F., Wang X., Dobbin M., and Tsai L.H. Recovery of learning and memory is associated with chromatin remodelling. Nature 447 (2007) 178-182
42. Dompierre J.P., Godin J.D., Charrin B.C., Cordelieres F.P., King S.J., Humbert S., and Saudou F. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 27 (2007) 3571-3583
43. Rai M., Soragni E., Jenssen K., Burnett R., Herman D., Coppola G., Geschwind D.H., Gottesfeld J.M., and Pandolfo M. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3 (2008) e1958
44. Chen Y., He R., Chen Y., D'Annibale M.A., Langley B., and Kozikowski AP:. Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors. ChemMedChem 4 (2009) 842-852
45. Kim S.J., Lee B.H., Lee Y.S., and Kang K.S. Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann-Pick type C disease improved by valproic acid, a histone deacetylase inhibitor. Biochem Biophys Res Commun 360 (2007) 593-599
46. Hauke J., Riessland M., Lunke S., Eyupoglu I.Y., Blumcke I., El-Osta A., Wirth B., and Hahnen E. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet 18 (2009) 304-317
47. Heo H., Yoo L., Shin K.S., and Kang S.J. Suppression of caspase-11 expression by histone deacetylase inhibitors. Biochem Biophys Res Commun 378 (2009) 79-83
48. Choi Y., Park S.K., Kim H.M., Kang J.S., Yoon Y.D., Han S.B., Han J.W., Yang J.S., and Han G. Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model. Exp Mol Med 40 (2008) 574-581
49. Zhang B., West E.J., Van K.C., Gurkoff G.G., Zhou J., Zhang X.M., Kozikowski A.P., and Lyeth B.G. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res 1226 (2008) 181-191
50. Nasu Y., Nishida K., Miyazawa S., Komiyama T., Kadota Y., Abe N., Yoshida A., Hirohata S., Ohtsuka A., and Ozaki T. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 16 (2008) 723-732
51. Bieliauskas A.V., and Pflum M.K. Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 37 (2008) 1402-1413
52. Estiu G., Greenberg E., Harrison C.B., Kwiatkowski N.P., Mazitschek R., Bradner J.E., and Wiest O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J Med Chem 51 (2008) 2898-2906
53. Weerasinghe S.V., Estiu G., Wiest O., and Pflum M.K. Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors. J Med Chem 51 (2008) 5542-5551
54. Jones P., Altamura S., De Francesco R., Paz O.G., Kinzel O., Mesiti G., Monteagudo E., Pescatore G., Rowley M., Verdirame M., et al. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J Med Chem 51 (2008) 2350-2353
55. Oyelere A.K., Chen P.C., Guerrant W., Mwakwari S.C., Hood R., Zhang Y., and Fan Y. Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem 52 (2009) 456-468
56. Methot J.L., Hamblett C.L., Mampreian D.M., Jung J., Harsch A., Szewczak A.A., Dahlberg W.K., Middleton R.E., Hughes B., Fleming J.C., et al. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 18 (2008) 6104-6109
57. Witter D.J., Harrington P., Wilson K.J., Chenard M., Fleming J.C., Haines B., Kral A.M., Secrist J.P., and Miller T.A. Optimization of biaryl selective HDAC1&2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 18 (2008) 726-731
58. Kattar S.D., Surdi L.M., Zabierek A., Methot J.L., Middleton R.E., Hughes B., Szewczak A.A., Dahlberg W.K., Kral A.M., Ozerova N., et al. Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization. Bioorg Med Chem Lett 19 (2009) 1168-1172
59. Jones P., Bottomley M.J., Carfi A., Cecchetti O., Ferrigno F., Lo Surdo P., Ontoria J.M., Rowley M., Scarpelli R., Schultz-Fademrecht C., et al. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg Med Chem Lett 18 (2008) 3456-3461
60. Muraglia E., Altamura S., Branca D., Cecchetti O., Ferrigno F., Orsale M.V., Palumbi M.C., Rowley M., Scarpelli R., Steinkuhler C., et al. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg Med Chem Lett 18 (2008) 6083-6087
61. Methot J.L., Chakravarty P.K., Chenard M., Close J., Cruz J.C., Dahlberg W.K., Fleming J., Hamblett C.L., Hamill J.E., Harrington P., et al. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 18 (2008) 973-978
62. Smil D.V., Manku S., Chantigny Y.A., Leit S., Wahhab A., Yan T.P., Fournel M., Maroun C., Li Z., Lemieux A.M., et al. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Bioorg Med Chem Lett 19 (2009) 688-692
63. Kozikowski A.P., Tapadar S., Luchini D.N., Kim K.H., and Billadeau D.D. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem 51 (2008) 4370-4373
64. Butler K.V., and Kozikowski A.P. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 14 (2008) 505-528